Date: 14th September 2021 at 18:00 CET
Speaker: Dr.Yael Porat (IL) Moderator: Dr. Dganit Itzhaky (IL) Webinar manager: Dr. Svetlana Evgina (RU)
The speaker will present a unique patented technology employing activated immune dendritic cellsc that specifically direct stem/progenitor cell therapeutic activity in-vitro which results in an enriched endothelial progenitor cells (EnEPCs; BGC101) product generated from a standard blood draw within a day. She will report long-term outcomes of a " first in human "pilot study of BGC101 for treating patients with severe Critical Limb Ischemia (CLI) with no available surgical option. Stem/progenitor cell treatments with bone-marrow-derived cells show promise in treating CLI, albeit not without adverse events related to cell mobilization and collection. As of 2020, 4 years after treatment, the therapy shows promising therapeutic effects in objective outcomes including limb salvage, increased leg blood flow and wound healing, as well as in walking ability, reduction of pain, decreased usage of narcotic medications and improved quality of life.
The webinar is accessible for EFLM Academy members only.